ReviewMedicine2025
Pulmonary arterial hypertension caused by coadministration of dasatinib and voriconazole: A case report and literature review.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Invasive Pulmonary Aspergillosis in an Immunocompetent Patient Following Occupational Exposure to Iron Oxide Dust: A Long-Term Follow-Up Case Report.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationaleIt has been demonstrated that azole antifungal agents can significantly increase the plasma concentration of dasatinib. Therefore, it is recommended to reduce the dasatinib dose to 20 to 40 mg daily for patients receiving voriconazole. However, the safety of coadministering dasatinib and voriconazole remains unclear. PATIENT CONCERNS: A 49-year-old woman with Philadelphia chromosome-positive acute lymphoblastic leukemia and invasive pulmonary aspergillosis reported dyspnea during therapy with reduced-dose dasatinib and standard-dose voriconazole. DIAGNOSES: Echocardiography revealed pleural effusion and a mean pulmonary arterial pressure of 40 mm Hg, suggesting pulmonary arterial hypertension.
interventionsDasatinib was discontinued and flumatinib was initiated. OUTCOMES: The patient's mean pulmonary arterial pressure was monitored and gradually normalized. LESSONS: Despite recommendations to reduce the dasatinib dose to 20 to 40 mg daily for patients on voriconazole, the enhanced effect of dasatinib due to voriconazole coadministration may contribute to the development of pulmonary arterial hypertension. Regular echocardiography follow-up is essential for patients concurrently taking azole antifungal agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.